Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Completed · Phase 1
Conditions studied: Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan and gemcitabine in treating patients who have unresectable or metastatic solid tumors.
Key facts
- Study ID
- NCT00004095
- Run by
- Northwestern University
- People needed
- 38
- Starts
- 1999-08-01
- Expected to finish
- 2008-10-01
- Last updated by the study team
- 2017-04-18
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.